A Phase 4 interventional study of Dapagliflozin and Glimepiride in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 14 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 76th largest by enrollment, is one of 19 that started in 2016, is one of 77 in phase 4, and was the 69th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 19 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 149th largest by enrollment of the 280 interventional ones that give a count, is one of 12 that started in 2016, is one of 28 in phase 4, and was the 255th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.
This is a 52 weeks, randomized, open-label, parallel-group, multi-centres phase IV study.
Participants will be randomized 1:1 to receive dapagliflozin 10 mg qd or glimepiride 1\~2 mgqd in an open-label manner for 12 months as add-on to metformin 1000 mg.
Parallel group study design was chosen. In order maintain the practicality of the phase IV study, open label design of study drug delivery was chosen. The reading of the DXA scans will be conducted by one expert in blinded manner. Glimepiride is the most frequently used SUs in Korea and therefore this was chosen as comparator.Dapagliflozin treatment will be associated with reduction of total body FM, BW, abdominal VAT and SAT volume compared with glimepiride.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin 10mg + Metformin 1000mg
Drug: Dapagliflozin
Glimepiriide 1-2mg + Metformin 1000mg
Drug: Glimepiride
Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan
Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment
Time frame: From baseline to Week 52
Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan
Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment
Time frame: From baseline to Week 52
Adjusted Mean Change in HbA1c at Week 52
Adjusted Mean Change in HbA1c at Week 52
Time frame: From baseline to Week 52
HbA1c <7.0% at Week 52
HbA1c \<7.0% at Week 52
Time frame: 52 weeks
Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52
Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Total Body Weight at Week 52
Adjusted Mean Change in Total Body Weight at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Waist Circumference at Week 52
Adjusted Mean Change in Waist Circumference at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Body Mass Index (BMI) at Week 52
Adjusted Mean Change in Body Mass Index (BMI) at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52
Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52
Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52
Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52
Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52
Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Lean Body Mass at Week 52
Adjusted Mean Change in Lean Body Mass at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in Adinopectin at Week 52
Adjusted Mean Change in Adinopectin at Week 52
Time frame: From baseline to Week 52
Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52
Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52
Time frame: From baseline to Week 52
First patient enrolled: 05 January 2016 Last patient last visit: 15 January 2018
| Milestone | Dapagliflozin | Glimepiride |
|---|---|---|
| Started | 60 | 61 |
| Completed | 52 | 54 |
| Not completed | 8 | 7 |
Adjusted mean changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment
| grams | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan | -1485.69 (-2025.543 to -945.844) | 1096.34 (556.489 to 1636.187) |
Adjusted Mean Change in HbA1c at Week 52
| percentages | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in HbA1c at Week 52 | -1.00 (-1.259 to -0.745) | -0.54 (-0.802 to -0.287) |
HbA1c \<7.0% at Week 52
| Participants | Dapagliflozin | Glimepiride |
|---|---|---|
| Count of participants that achieved the response | 27 | 22 |
Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52
| mg/dL | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52 | -30.94 (-40.084 to -21.800) | -12.70 (-21.786 to -3.607) |
Adjusted Mean Change in Total Body Weight at Week 52
| kg | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Total Body Weight at Week 52 | -2.4 (-3.104 to -1.664) | 1.3 (0.545 to 1.984) |
Adjusted Mean Change in Waist Circumference at Week 52
| cm | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Waist Circumference at Week 52 | -2.37 (-3.480 to -1.253) | -0.16 (-1.271 to 0.957) |
Adjusted Mean Change in Body Mass Index (BMI) at Week 52
| kg/m^2 | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Body Mass Index (BMI) at Week 52 | -0.91 (-1.172 to -0.640) | 0.46 (0.194 to 0.726) |
Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52
| mmHg | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52 | -2.18 (-5.123 to 0.766) | 4.63 (1.682 to 7.570) |
Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52
| mmHg | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52 | -0.25 (-2.523 to 2.023) | 2.36 (0.092 to 4.638) |
Adjusted Mean Change in Visceral Adipose Tissue (VAT) area at Week 52
| cm^2 | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52 | -16.06 (-23.806 to -8.317) | 1.48 (-6.407 to 9.377) |
Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) area at Week 52
| cm^2 | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Subcutaneous Adipose Tissue (SAT) Area at Week 52 | -5.41 (-11.804 to 0.994) | 12.98 (6.462 to 19.506) |
Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52
| ratio | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Visceral to Subcutaneous Adipose Tissue Ratio at Week 52 | -0.05 (-0.115 to 0.017) | -0.02 (-0.084 to 0.050) |
Adjusted Mean Change in Lean Body Mass at Week 52
| Kg | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Lean Body Mass at Week 52 | -1.1 (-1.608 to -0.570) | 0.2 (-0.329 to 0.683) |
Adjusted Mean Change in Adinopectin at Week 52
| ng/mL | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in Adinopectin at Week 52 | 1746.66 (1296.144 to 2197.181) | 1088.95 (638.431 to 1539.468) |
Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52
| mg/L | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Change in High Sensitivity C-Reactive Protein (hsCRP) at Week 52 | -0.51 (-1.030 to 0.014) | -0.39 (-0.914 to 0.131) |
Adjusted mean percent changes in total body fat mass from baseline using DXA scan in 52 weeks after the start of the treatment
| percent change | Dapagliflozin | Glimepiride |
|---|---|---|
| Adjusted Mean Changes From Baseline in Percentage of Total Body Fat Assessed by DXA Scan | -1.21 (-1.821 to -0.604) | 0.73 (0.123 to 1.341) |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin | 0/60 (0%) | 6/60 (10%) | 11/60 (18.3%) |
| Glimepiride | 0/61 (0%) | 6/61 (9.8%) | 10/61 (16.4%) |
| Event | Dapagliflozin | Glimepiride |
|---|---|---|
| Rib fractureInjury, poisoning and procedural complications | 1/60 | 0/61 |
| Splenic injuryInjury, poisoning and procedural complications | 1/60 | 0/61 |
| Subdural haemorrhageInjury, poisoning and procedural complications | 1/60 | 0/61 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/60 | 0/61 |
| Transient ischaemic attackNervous system disorders | 1/60 | 0/61 |
| Conversion disorderPsychiatric disorders | 1/60 | 0/61 |
| Tibia fractureInjury, poisoning and procedural complications | 1/60 | 0/61 |
| Pyelonephritis acuteInfections and infestations | 0/60 | 1/61 |
| Ankle fractureInjury, poisoning and procedural complications | 0/60 | 1/61 |
| Joint dislocationInjury, poisoning and procedural complications | 0/60 | 1/61 |
| Event | Dapagliflozin | Glimepiride |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 3/60 | 7/61 |
| ToothacheGastrointestinal disorders | 4/60 | 1/61 |
| NasopharyngitisInfections and infestations | 4/60 | 2/61 |
| Age, Continuous(years) | Dapagliflozin | Glimepiride | Total |
|---|---|---|---|
| Mean | 54.6 ± 9.09 | 55.7 ± 10.24 | 55.2 ± 9.66 |
| Sex: Female, Male(Participants) | Dapagliflozin | Glimepiride | Total |
|---|---|---|---|
| Female | 23 | 34 | 57 |
| Male | 37 | 27 | 64 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin | Glimepiride | Total |
|---|---|---|---|
| Korean | 60 | 61 | 121 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Jan 2018, 24 months.
Results were first posted in Aug 2019, 1 year 7 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 24 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin